IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.546
EU - Europa 1.319
AS - Asia 259
SA - Sud America 5
OC - Oceania 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.133
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.539
IE - Irlanda 427
SE - Svezia 242
IT - Italia 215
SG - Singapore 143
DE - Germania 119
UA - Ucraina 114
GB - Regno Unito 103
IN - India 66
CN - Cina 26
FI - Finlandia 22
BE - Belgio 15
FR - Francia 15
DK - Danimarca 11
KR - Corea 7
RO - Romania 7
JP - Giappone 6
CA - Canada 5
RU - Federazione Russa 5
NL - Olanda 4
BG - Bulgaria 3
BR - Brasile 3
LU - Lussemburgo 3
AU - Australia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
ES - Italia 2
IL - Israele 2
MX - Messico 2
PL - Polonia 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CH - Svizzera 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IS - Islanda 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MY - Malesia 1
NP - Nepal 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
VN - Vietnam 1
Totale 9.133
Salva come PNG Salva come JPEG
Città #
Des Moines 1.470
Chandler 1.178
Fairfield 666
Ashburn 579
Dublin 419
Wilmington 345
Woodbridge 282
Houston 249
Seattle 245
Cambridge 214
Jacksonville 199
Lawrence 167
Princeton 167
San Mateo 142
Ann Arbor 135
Boardman 120
New York 116
San Diego 100
Washington 73
Redmond 72
Pune 65
London 40
Falls Church 31
Ancona 22
Helsinki 21
Norwalk 19
Turin 17
Beijing 15
Brussels 15
Prescot 10
Forlì 9
Rome 9
Centro 8
Edinburgh 7
Strasbourg 7
Cagliari 6
Menlo Park 6
Southwark 6
Chicago 5
Hounslow 5
Marche 5
Nanjing 5
Stockholm 5
Canosa di Puglia 4
Kilburn 4
Marano di Valpolicella 4
Phoenix 4
Redwood City 4
Buffalo 3
Frankfurt am Main 3
New Bedfont 3
Pesaro 3
Portland 3
Saint Petersburg 3
Sofia 3
Tokyo 3
Toronto 3
Torre Del Greco 3
Wandsworth 3
Amsterdam 2
Antalya 2
Appignano 2
Augusta 2
Brasília 2
Campobasso 2
Chiswick 2
Città di Castello 2
Civitanova Marche 2
Falconara Marittima 2
Fuzhou 2
Kagoya 2
Las Vegas 2
Los Angeles 2
Luxembourg 2
Macerata 2
Madrid 2
Medellín 2
Milan 2
Montelupone 2
Montreal 2
Ostra Vetere 2
Prague 2
San Benedetto del Tronto 2
San Costanzo 2
San Jose 2
Senigallia 2
Slobozia 2
Sydney 2
Tel Aviv 2
Tolentino 2
Trecate 2
Warsaw 2
Acton 1
Astana 1
Atlanta 1
Barbara 1
Belgrade 1
Biratnagar 1
Bolton 1
Borca 1
Totale 7.403
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 146
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 122
Immunotherapy in genitourinary cancers: Where are we going? 112
Are liver nested stromal epithelial tumors always low aggressive? 105
Microbiome and cancers, with focus on genitourinary tumors 99
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 94
Molecular diagnostics in uro-oncology 91
From undergraduate medical school student to visible pathologist 89
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 88
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 83
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 81
Is There a Role for Immunotherapy in Prostate Cancer? 80
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 78
Pd-l1 inhibitors for the treatment of prostate cancer 78
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 77
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 75
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 75
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 75
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 74
The human microbiota and prostate cancer: Friend or foe? 74
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 74
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 74
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 73
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 71
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 71
Epigenetic modifications and modulators in prostate cancer 71
Exploring the Spectrum of Kidney Ciliopathies 71
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 70
null 70
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 70
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 69
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 68
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 67
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 67
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 66
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 66
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 66
Molecular characterization of testicular germ cell tumors using tissue microdissection 66
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 66
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 65
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 65
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 64
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 64
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 63
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 63
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 63
Quick steps toward precision medicine in renal cell carcinoma 63
Pathology without microscope: From a projection screen to a virtual slide 63
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 63
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 63
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 62
null 62
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 62
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 62
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 62
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 62
null 62
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 61
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 61
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 61
Emerging molecular technologies in genitourinary tumors 61
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 61
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 61
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 61
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 61
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 61
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 61
Immunotherapy and radiation therapy in renal cell carcinoma 60
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now 60
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 59
The identification of immunological biomarkers in kidney cancers 59
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 59
Variants of Bladder Cancer: The Pathologist's Point of View 59
Editorial: Emerging biomarkers in genitourinary tumors 58
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 58
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 58
Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: A narrative review 58
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 58
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 57
Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? 57
Epigenetic modulations and lineage plasticity in advanced prostate cancer 57
Treating prostate cancer by antibody-drug conjugates 57
Emerging molecular technologies in renal cell carcinoma: Liquid biopsy 56
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 56
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 56
Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme 56
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 56
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 56
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 55
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 55
Renal Cell Carcinoma: genomic landscape and clinical implications 55
Immune checkpoint inhibitors for the treatment of bladder cancer 55
null 53
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 53
Pd-l1 testing for urothelial carcinoma: Interchangeability, reliability and future perspectives 53
Variants and new entities of bladder cancer 52
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 52
null 52
Bone targeting agents in patients with metastatic prostate cancer: State of the art 52
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 52
Totale 6.704
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.728
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.728
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20199 0 0 0 0 0 0 0 0 0 5 1 3
2019/2020151 2 0 7 0 16 4 15 2 21 11 31 42
2020/20212.174 38 40 68 63 224 762 182 186 138 200 230 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.316 282 45 138 162 248 358 22 49 5 7 0 0
Totale 9.338